PURPOSE: The microRNA-29 (miR-29) family has emerged, in various tissues, as a key modulator of extracellular matrix (ECM) homeostasis. In this study, the authors investigate the role of the miR-29 family in the regulation of ECM synthesis in the trabecular meshwork (TM) under basal and TGF-β2 stimulatory conditions. METHODS: Human TM cells were incubated with 2.5 ng/mL activated, recombinant human TGF-β2 for 24, 48, and 72 hours. A specific pharmacologic inhibitor was used to block SMAD3 function in the context of TGF-β2 stimulation. Changes in the expression of the miR-29 family were assessed by real-time PCR. The effect of miR-29 molecules and inhibitors on ECM levels was determined by immunoblot analysis. RESULTS: All three members of the miR-29 family were expressed in cultured TM cells. Although the incubation of TM cells with TGF-β2 induced miR-29a and suppressed miR-29b levels, no significant effect was observed on miR-29c expression. Additional studies revealed that SMAD3 modulates miR-29b expression under basal and TGF-β2 conditions. Subsequent gain- and loss-of-function experiments demonstrated that the miR-29 family functions as a critical suppressor of various ECM proteins under basal and TGF-β2 stimulatory conditions. CONCLUSIONS: The findings derived from this study identify the miR-29 family as a critical regulator of ECM expression in the TM and suggest that its modulation by TGF-β2 may be important in controlling ECM synthesis. Together, these data provide further insight into the complex regulatory mechanisms mediating TGF-β2 signaling and ECM production in the TM.
PURPOSE: The microRNA-29 (miR-29) family has emerged, in various tissues, as a key modulator of extracellular matrix (ECM) homeostasis. In this study, the authors investigate the role of the miR-29 family in the regulation of ECM synthesis in the trabecular meshwork (TM) under basal and TGF-β2 stimulatory conditions. METHODS:Human TM cells were incubated with 2.5 ng/mL activated, recombinant human TGF-β2 for 24, 48, and 72 hours. A specific pharmacologic inhibitor was used to block SMAD3 function in the context of TGF-β2 stimulation. Changes in the expression of the miR-29 family were assessed by real-time PCR. The effect of miR-29 molecules and inhibitors on ECM levels was determined by immunoblot analysis. RESULTS: All three members of the miR-29 family were expressed in cultured TM cells. Although the incubation of TM cells with TGF-β2 induced miR-29a and suppressed miR-29b levels, no significant effect was observed on miR-29c expression. Additional studies revealed that SMAD3 modulates miR-29b expression under basal and TGF-β2 conditions. Subsequent gain- and loss-of-function experiments demonstrated that the miR-29 family functions as a critical suppressor of various ECM proteins under basal and TGF-β2 stimulatory conditions. CONCLUSIONS: The findings derived from this study identify the miR-29 family as a critical regulator of ECM expression in the TM and suggest that its modulation by TGF-β2 may be important in controlling ECM synthesis. Together, these data provide further insight into the complex regulatory mechanisms mediating TGF-β2 signaling and ECM production in the TM.
Authors: Debra L Fleenor; Allan R Shepard; Peggy E Hellberg; Nasreen Jacobson; Iok-Hou Pang; Abbot F Clark Journal: Invest Ophthalmol Vis Sci Date: 2006-01 Impact factor: 4.799
Authors: E Anastasiadou; F Boccellato; S Vincenti; P Rosato; I Bozzoni; L Frati; A Faggioni; C Presutti; P Trivedi Journal: Oncogene Date: 2009-12-07 Impact factor: 9.867
Authors: M G Hattenhauer; D H Johnson; H H Ing; D C Herman; D O Hodge; B P Yawn; L C Butterfield; D T Gray Journal: Ophthalmology Date: 1998-11 Impact factor: 12.079
Authors: Tetsuya Toyono; Tomohiko Usui; Guadalupe Villarreal; Laura Kallay; Mario Matthaei; Lucas M M Vianna; Angela Y Zhu; Masahiko Kuroda; Shiro Amano; Albert S Jun Journal: Cornea Date: 2016-11 Impact factor: 2.651
Authors: Lyndsay V Rhodes; Syreeta L Tilghman; Stephen M Boue; Shuchun Wang; Hafez Khalili; Shannon E Muir; Melyssa R Bratton; Qiang Zhang; Guangdi Wang; Matthew E Burow; Bridgette M Collins-Burow Journal: Oncol Lett Date: 2011-10-24 Impact factor: 2.967
Authors: Mario Matthaei; Jianfei Hu; Laura Kallay; Charles G Eberhart; Claus Cursiefen; Jiang Qian; Eva-Maria Lackner; Albert S Jun Journal: Invest Ophthalmol Vis Sci Date: 2014-01-09 Impact factor: 4.799